In contrast, a strong negative correlation exists between the aggressiveness of solid tumours and kinase-dead EPHB6, with EPHB6 expression frequently reduced in aggressive malignancies, including invasive melanoma [5], metastatic lung and colorectal cancers [6], aggressive neuroblastoma [7, 8], prostate, gastric and ovarian tumours [9–11]. The gene discussed is EPHB6; the disease is colorectal cancer.